Pemvidutide

Pemvidutide (ALT-801) is a GLP-1/glucagon dual receptor agonist peptide developed by Altimmune, Inc., a clinical-stage biopharmaceutical company. Pemvidutide represents Altimmune's lead asset, combining the appetite-suppressing effects of GLP-1 activation with the energy-expenditure-enhancing effects of glucagon activation.

Unlike oral non-peptide GLP-1 agonists, pemvidutide is peptide-based and administered via subcutaneous injection, similar to semaglutide or tirzepatide. The dual agonist mechanism positions pemvidutide as a midway point between single GLP-1 agonists (semaglutide) and triple agonists (retatrutide), potentially offering improved efficacy over single agonists with potentially better tolerability than triple combinations.

Altimmune is also developing intranasal immunotherapy programs and has positioned pemvidutide as a key growth driver, with significant partnership interest from larger pharmaceutical companies seeking dual agonist assets for obesity and metabolic disease.

GLP-1 receptor activation: Pemvidutide activates GLP-1 receptors throughout the brain, gut, and endocrine pancreas, reducing appetite, slowing gastric emptying, and enhancing insulin secretion in response to elevated blood glucose.

Glucagon receptor activation: Simultaneous glucagon receptor activation increases hepatic and systemic energy expenditure, promotes fat oxidation in the liver and adipose tissue, and improves lipid metabolism.

Complementary mechanisms: The combination of reduced caloric intake (GLP-1) and increased caloric expenditure (glucagon) creates a dual-pronged weight loss approach that addresses both sides of the energy balance equation.

Organ-specific benefits: Glucagon activation particularly benefits liver health by promoting hepatic fat oxidation, potentially reducing non-alcoholic fatty liver disease (NAFLD) and improving hepatic insulin sensitivity alongside weight loss.

Phase 2 trial results: Altimmune's Phase 2 trial of pemvidutide showed dose-dependent weight loss with mean reductions of approximately 15-18% across the primary efficacy groups over 12-16 weeks of treatment.

Dosing regimens tested: Clinical trials have evaluated different dosing frequencies including once-weekly and twice-weekly subcutaneous administration, with various dose levels ranging from 3-8 mg.

Metabolic improvements: Beyond weight loss, trials documented improvements in fasting glucose, HbA1c, triglycerides, and liver health markers (ALT, AST), supporting broader metabolic benefit.

NASH/MASH indication: Altimmune is also studying pemvidutide in patients with NASH (now called MASH - metabolic dysfunction-associated steatohepatitis), as glucagon activation may particularly benefit liver fat reduction and inflammation.

Tolerability profile: Early data reports gastrointestinal side effects consistent with GLP-1 class drugs, with rates potentially lower than some triple agonists.

• Substantial weight loss — dual mechanism targeting appetite and energy expenditure
• Metabolic improvements — better glucose control, improved lipid profiles
• Liver health — glucagon-driven hepatic fat oxidation beneficial for NAFLD/MASH
• Energy expenditure increase — glucagon activation boosts metabolic rate
• Cardiovascular benefits — weight loss and metabolic improvements support heart health
• Potentially favorable tolerability — dual agonist may have better GI side effect profile than triple agonists
• Flexible dosing — once or twice-weekly options depending on patient preference and response

Clinical trial dosing: Pemvidutide is administered via subcutaneous injection, with Phase 2 trials evaluating once-weekly and twice-weekly dosing regimens at doses ranging from 3-8 mg per injection.

Dose escalation: Protocols typically use gradual escalation from lower starting doses to target maintenance doses, with adjustments made every 2-4 weeks based on tolerability and response.

Administration sites: Like other injectable peptides, pemvidutide is injected subcutaneously in areas with adequate subcutaneous tissue (abdomen, thigh, upper arm), with site rotation recommended to minimize injection site reactions.

Current availability: Pemvidutide is investigational and available only in registered clinical trials. It is not FDA-approved or commercially available.

Gastrointestinal side effects: Nausea (10-25%), diarrhea (10-20%), vomiting (5-12%), and constipation (5-10%) have been reported in Phase 2 trials. Most are mild to moderate and transient, improving over time as the body adapts.

Injection site reactions: Mild redness, swelling, or discomfort at injection sites occur in some patients, typically resolving with proper injection technique and site rotation.

Safety considerations: As a GLP-1/glucagon agonist, pemvidutide carries similar safety considerations as other GLP-1 drugs: theoretical pancreatitis risk (rare), potential thyroid C-cell concerns from GLP-1 class (monitored but not confirmed in human trials), and contraindication in medullary thyroid carcinoma history.

Metabolic monitoring: Fasting glucose may transiently increase early in treatment before overall glucose control improves. Lean muscle mass may decrease alongside fat loss, making resistance training important to preserve muscle during treatment.